Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

dc.contributor.author

McLellan, JS

dc.contributor.author

Pancera, M

dc.contributor.author

Carrico, C

dc.contributor.author

Gorman, J

dc.contributor.author

Julien, JP

dc.contributor.author

Khayat, R

dc.contributor.author

Louder, R

dc.contributor.author

Pejchal, R

dc.contributor.author

Sastry, M

dc.contributor.author

Dai, K

dc.contributor.author

O'Dell, S

dc.contributor.author

Patel, N

dc.contributor.author

Shahzad ul Hussan, S

dc.contributor.author

Yang, Y

dc.contributor.author

Zhang, B

dc.contributor.author

Zhou, T

dc.contributor.author

Zhu, J

dc.contributor.author

Boyington, JC

dc.contributor.author

Chuang, GY

dc.contributor.author

Diwanji, D

dc.contributor.author

Georgiev, I

dc.contributor.author

Kwon, YD

dc.contributor.author

Lee, D

dc.contributor.author

Louder, MK

dc.contributor.author

Moquin, S

dc.contributor.author

Schmidt, SD

dc.contributor.author

Yang, ZY

dc.contributor.author

Bonsignori, M

dc.contributor.author

Crump, JA

dc.contributor.author

Kapiga, SH

dc.contributor.author

Sam, NE

dc.contributor.author

Haynes, BF

dc.contributor.author

Burton, DR

dc.contributor.author

Koff, WC

dc.contributor.author

Walker, LM

dc.contributor.author

Phogat, S

dc.contributor.author

Wyatt, R

dc.contributor.author

Orwenyo, J

dc.contributor.author

Wang, LX

dc.contributor.author

Arthos, J

dc.contributor.author

Bewley, CA

dc.contributor.author

Mascola, JR

dc.contributor.author

Nabel, GJ

dc.contributor.author

Schief, WR

dc.contributor.author

Ward, AB

dc.contributor.author

Wilson, IA

dc.contributor.author

Kwong, PD

dc.coverage.spatial

England

dc.date.accessioned

2017-03-02T19:25:40Z

dc.date.available

2017-03-02T19:25:40Z

dc.date.issued

2011-11-23

dc.description.abstract

Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/22113616

dc.identifier

nature10696

dc.identifier.eissn

1476-4687

dc.identifier.uri

https://hdl.handle.net/10161/13795

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

Nature

dc.relation.isversionof

10.1038/nature10696

dc.subject

AIDS Vaccines

dc.subject

Amino Acid Motifs

dc.subject

Amino Acid Sequence

dc.subject

Antibodies, Neutralizing

dc.subject

Antibody Affinity

dc.subject

Antibody Specificity

dc.subject

Antigen-Antibody Complex

dc.subject

Binding Sites, Antibody

dc.subject

Conserved Sequence

dc.subject

Crystallography, X-Ray

dc.subject

Epitopes

dc.subject

Glycopeptides

dc.subject

Glycosylation

dc.subject

HIV Antibodies

dc.subject

HIV Envelope Protein gp120

dc.subject

HIV-1

dc.subject

Hydrogen Bonding

dc.subject

Immune Evasion

dc.subject

Models, Molecular

dc.subject

Molecular Sequence Data

dc.subject

Polysaccharides

dc.subject

Protein Structure, Quaternary

dc.subject

Protein Structure, Tertiary

dc.title

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

dc.type

Journal article

duke.contributor.orcid

Bonsignori, M|0000-0003-2973-2101

duke.contributor.orcid

Crump, JA|0000-0002-4529-102X

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/22113616

pubs.begin-page

336

pubs.end-page

343

pubs.issue

7377

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Human Vaccine Institute

pubs.organisational-group

Global Health Institute

pubs.organisational-group

Immunology

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Duke Human Vaccine Institute

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

Pathology

pubs.organisational-group

School of Medicine

pubs.organisational-group

University Institutes and Centers

pubs.publication-status

Published online

pubs.volume

480

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Nature_gp120V1V2Structure.pdf
Size:
2.4 MB
Format:
Adobe Portable Document Format